Pharmacovigilance

Concerns on monitoring of drug safety

Evaluation of safety information's is primarily based on reporting of suspected adverse reactions by physician prescribing the medicine.

In the case of suspicion on adverse reaction of our products we are continuously available.

MUDr. Jaromír Frič, CSc.
24-hod. tel.: +420 602 440 229
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ico telefon